Abstractor Interview New York, NY (US). Flatiron’s former CMO & CSO, Amy Abernethy, and Dr. Rick Pazdur of the FDA discuss the agency’s engagement with real-world evidence, the path forward for RWE, and the future of cancer care at the 2018 Flatiron Research Summit. Castellanos E, Orlando A, Hamrick J, Ma X, O'Connell G, Meropol NJ, Adamson B. Bennette CS, Nussbaum NC, Curtis MD, Meropol NJ, Bartlett CH, Mardekian J, Yu-Kite M, Cotter MJ, Kim S, Decembrino J, Snow T, Carson KR, Rockland JM, Kraus AL, Wilner KD, Oharu N, Schnell P, Lu D, Tursi J, Doebele RC, Perez L, Trinh H, Martinec M, Martina R, Riehl T, Krebs M, Meropol NJ, Wong WB, Crane G, Riely GJ, Lovly CM, Messina C, Bienert S, Alexander K, Pao W, Baxi S, Doebele RC, Willard MD, Smyth EN, Tiu RV, Beyrer J, Zhu YE, Bowman L, Sheffield KM, Han Y, Brastianos P, Giri S, Huntington SF, Wang R, Zeidan AM, Podoltsev NA, Gore S, Ma X, Gross CP, Davidoff AJ, Neparidze N. Garcia R, Dwyer A, Worrall S, Heery CR, Deming DA, Benson AB, Davis A. McLaurin K, Dalvi T, Collins JM, Nordstrom BL, McCutcheon S, Bennett JC, Murphy BR, Singhal PK, Briceno JM, Morgans AK, Rahma OE, Mhatre, SK, Chuo C-Y, Davies J, Martinalbo J, Davarpanah NN, Pachynski R. Richardson PG, Jagannath S, Chari A, Vogl DT, Dimopoulos MA, Moreau P, Dingli D, Wei LJ, Li L, Tang S, Reichman W, Kauffman MG, Shah JJ, Shacham S, Lonial S. Soff GA, Shaw J, Kilpatrick K, Marongiu A, Park J. Batus M, Stefaniak VJ, Molife C, Clarke JM, Winfree KB, Mitchell L, Cui ZL, Bonom PD, John A, Shah R, Wong WB, Schneider C, Gari HH, Johnson M. Bagley SJ, Dhopeshwarkar N, Narayan V, Meropol NJ, Mamtani R, Boursi B. Clarke JM, Mathur R, Molife C, Batus M, Stefaniak VJ, Winfree KB, Baxi S, Cui ZL, Lenis D, Bonomi PD, Feld E, Harton J, Meropol NJ, Adamson B, Parikh RB, Galsky MD, Cohen AB, Narayan V, Christodouleas JP, Vaughn DJ, Hubbard RA, Mamtani R, Shore ND, Sartor AO, Sternberg CN, Saad F, Tombal BF, Miller K, Kalinovsky J, Jiao X, Tangirala K, Higano CS, Westin SN, Louie-Gao M, Badamgarav E, Bala MV, Thaker PH, Mascaux C, Bubendorf L, Barlesi F, Clendening JW, Zhang Q, Mace K, Gondos A, Foser S, Wang L, Paz-Ares LG, Leapman M, Presley CJ, Zhu W, Soulos PR, Adelson KB, Boffa DJ, Gross CP, Smyth EN, Tiu RV, Willard MD, Beyrer J, Zhu YE, Bowman L, Sheffield KM, Han Y, Brastianos P, Whipple S, Martin A, Martinec M, Arbour KC, Seshan VE, Riely GJ, Crane G, Shen R, Allan V, Mungul A, Diaz J, Luo T, Harish A, Ramagopalan S, Chang J, Hooley I, Cohen C, Gross G, Williams E, Adamson B, Hooley I, Chen R, Long L, Cohen A, Adamson B, Ambwani G, Cohen A, Estévez M, Singh N, Adamson B, Nussbaum N, Birnbaum B, Steuten L, Goulart B, Meropol N, Pritchard D, Ramsey S, Sebastian M, Barlesi F, Califano R, Mansfield AS, Blackhall F, Flahavan E, Davies J, Arnold P, Morris S, Reck M, Pan X, Lin MM, Yin Y, Hou P, Baumann P, Jahanzeb M. Frueh M, Rahma OE, Pachynski RK, Mazieres J, Goldschmidt, Jr J, Ton TGN, Mhatre SK, Chuo C-Y, Martinalbo J, Davies J, Juergens R. Backenroth D, Haimson JD, Meropol NJ, Baxi SS. Average salary: $65,454 I interviewed at Flatiron Health (United States). Health Details: I applied online. However, as with many jobs at this company and others, the decision makers are essentially looking for a type of personality to give their jobs to -- someone who is easy to manage and has a high tolerance to disorganization. Nurse Abstractor. Get quick access to information about Flatiron. Interview. Interview. When they purchased Altos Solutions in 2014, having a Electronic Medical Report product that was cancer focused did a lot towards those goals. Familiar with all aspects of how cancer is treated, from diagnosis to recovery, and fluent in cancer terminology; Knowledge and experience with AJCC staging I interviewed at Flatiron Health (New York, NY (US)) in November 2020. I felt that they intentionally tried to trick you in the medical records by the progress notes saying one thing vs the pathology report. They need to re-evaluate the assessment because I'm not the only one. Researchers, academics, oncologists, engineers and more all work together here to deliver better solutions. I applied online. Received an email with a link to an assessment. They had conflicting information reported in a disorganized record and wanted you to answer the questions based on their rules but didn’t give adequate information to do so according to the rules. I interviewed at Flatiron Health (United States). Got through the technical test and the medical records review. Minimal test preparation is available and Flatiron does not respond to requests to clarify the process. No interview, just an assessment. Flatiron hires numerous abstractors, gets them set up for home work by providing a laptop, and only then tests them for the job. The interview process was more streamlined than I have experienced at other companies. If you do not have access to the PMT then contact . A retrospective analysis based on real-world data, Real-world effectiveness of palbociclib in combination with an aromatase inhibitor as first-line therapy in metastatic breast cancer, Biomarker testing, treatment and survival outcomes in Medicaid compared to commercially insured patients with advanced NSCLC, Value of precision medicine in advanced NSCLC: Real-world outcomes associated with the use of companion diagnostics, Real-world outcomes of advanced melanoma patients treated with pembrolizumab who have failed prior lines of therapy, Impact of antibiotics on overall survival in patients with advanced non-small-cell lung cancer and melanoma treated with first-line immune checkpoint inhibition, Real-world clinical outcomes for advanced/metastatic non-small cell lung cancer patients treated with second line ramucirumab plus docetaxel post frontline platinum based chemotherapy plus immune checkpoint inhibitors, Real-world tumor response to ramucirumab plus docetaxel post platinum-based and immune checkpoint inhibitor therapy in advanced non-small cell lung cancer patients, Carboplatin-based chemotherapy versus immunotherapy in metastatic urothelial carcinoma, Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone plus prednisone/prednisolone: A retrospective study of real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer, Risk factors for progression or death in ovarian cancer patients who completed first-line platinum treatment, Identification and use of treatment options in patients with advanced non-small cell lung cancer after comprehensive genomic profiling: A real-world study, Real-world practice patterns and impact of PD-L1 expression testing in patients with advanced non-small cell lung cancer, Clinical characteristics, treatment patterns, and overall survival in advanced NSCLC patients with and without brain metastases, Validation of broad panel clinical sequencing-based genomic risk stratification in patients with advanced lung adenocarcinomas, The Impact of Delaying ALK Inhibitor Therapy on Outcomes: A Prescription Time Matching Method, Impact of Treatment Sequence on Overall Survival in Metastatic Pancreatic Cancer Patients with Liposomal Irinotecan in the Real-World Setting, Improving the Accuracy of Measuring Duration of Therapy by Identifying Patients Who Remain on Treatment in a Real-World Database, Real World Effectiveness of Nivolumab in Asian Patients in the United States Flatiron Health Database, Medicaid Expansion and Racial Inequities in Next Generation Sequencing Testing in Oncology, Optimization of Natural Language Processing-Supported Comorbidity Classification Algorithms in Electronic Health Records, Machine Learning Model for Cancer Biomarker Identification in Electronic Health Records, Cost-Effectiveness of Multi-Gene Panel Sequencing for Patients with Advanced Melanoma, Treatment characteristics and clinical outcomes in patients with extensive-stage small cell lung cancer treated with carboplatin or cisplatin in combination with etoposide in US clinical practice, Real-world immuno-oncology therapy treatment patterns and outcomes in patients with anaplastic lymphoma kinase positive non-small cell lung cancer in the United States, Treatment characteristics of patients with locally advanced or metastatic non-small cell lung cancer receiving atezolizumab monotherapy in US clinical practice, Development and initial validation of a prognostic score based on structured data from EHRs, Real-world outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic non-small cell lung cancer (NSCLC), Primary tumor location (PTL) and survival outcomes in a real world cohort of KRAS wild-type (WT) metastatic colorectal cancer (mCRC) patients, Real-world trends in first-line checkpoint inhibitor use in advanced urothelial cell carcinoma, Trends in checkpoint inhibitor therapy for advanced urothelial cell carcinoma at the end of life: Insights from real-world practice, Predictive value of fibroblast growth factor receptor mutations and gene fusions on anti-PD-(L)1 treatment outcomes in patients with advanced urothelial cancer, Treatment patterns and outcomes for metastatic castration-resistant prostate cancer in a real-world setting: A retrospective study of greater than 2500 patients, Treatment characteristics of patients with locally advanced or metastatic urothelial cancer receiving atezolizumab monotherapy in United States clinical practice, Clinical outcome with concurrent or layered treatment with radium-223 and abiraterone: A retrospective study of real-world experience with patients with metastatic castration-resistant prostate cancer, Survival of patients with metastatic HER2 positive gastroesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on frontline chemotherapy plus trastuzumab, Comparative effectiveness of nivolumab relative to standard of care for advanced/metastatic gastric or gastroesophageal junction cancer: A simulated treatment comparison, Line of Therapy Definition Impacts Analyses of Second-Line Survival in a Metastatic Pancreatic Cancer Electronic Health Record Database, First-line pembrolizumab monotherapy in metastatic PD-L1 positive non-small cell lung cancer: A real-world analysis of time on treatment in US community oncology practices, Temporally integrated framework for treatment intervals (TIFTI): A framework for extracting drug intervals from longitudinal clinic notes, Influence of Prognostic Factors on Outcomes Among Metastatic Breast Cancer Patients Treated with CDK4&6 Inhibitors in Routine Clinical Practice, Outcomes in patients (pts) with metastatic triple-negative breast cancer (mTNBC) treated in second line (2L) in the US real-world setting, A real world evidence study of BRCA mutations and survival in HER2-negative breast cancer, Time to treatment discontinuation of second-line fulvestrant monotherapy for HR+/HER2− metastatic breast cancer in the real-world setting, Real-world survival of heavily pretreated patients with refractory HR+, HER2- metastatic breast cancer receiving single-agent chemotherapy – A comparison with MONARCH 1, Hepatitis B Testing Rates in Patients with Chronic Lymphocytic Leukemia before and during Administration of Anti-CD20 Therapy, The Real-World Frequency of 24-Hour Urine Protein Electrophoresis (UPEP), Serum Free Light Chain (SFLC), and Serum Protein Electrophoresis (SPEP) Testing in Patients with Multiple Myeloma (MM), Real-World Disparities in Daratumumab Utilization for Patients with Relapsed or Refractory Multiple Myeloma (MM), Dynamic Changes in International Staging System As a Predictor of Survival Outcome in Patients with Advanced Multiple Myeloma, Results of the Pivotal STORM Study (Part 2) in Penta-Refractory Multiple Myeloma (MM): Deep and Durable Responses with Oral Selinexor Plus Low Dose Dexamethasone in Patients with Penta-Refractory MM, Treatment Patterns Among Adults with Newly Diagnosed Primary Immune Thrombocytopenia in the United States, Comparing Bortezomib-Lenalidomide-Dexamethasone (VRd) with Carfilzomib-Lenalidomide-Dexamethasone (KRd) in the Patients with Newly Diagnosed Multiple Myeloma (NDMM) in Two Observational Studies, Real-World Outcomes for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Lenalidomide, Bortezomib, and Dexamethasone, or Bortezomib and Dexamethasone: An Enhanced Electronic Health Records Database Analysis, Treatment Sequencing and Survival Outcomes in BRAF Mutation–Positive Metastatic Melanoma Patients Treated With Immunotherapy in Routine Clinical Practices in the United States, Adjuvant Therapy is Associated with Improved Overall Survival in Advanced Melanoma Patients in the United States, Real-World (RW) Effectiveness of First-Line (1L) Nivolumab (NIVO) Plus Ipilimumab (IPI) or NIVO Monotherapy for Advanced Melanoma (MEL): Subgroup Analysis of a Retrospective Cohort Study, Establishing the Need for Immuno-Oncology (IO) Therapy (tx) in Second-Line (2L) Small Cell Lung Cancer (SCLC), Real-World Dosing Patterns of Patients (Pts) With Metastatic Pancreatic Cancer (MPC) Treated With Liposomal Irinotecan (Nal-iri) in US Oncology Clinics, Assessment of Real-World Effectiveness of First-Line (1L) Nivolumab (NIVO) Plus Ipilimumab (IPI) or NIVO Monotherapy for Advanced Melanoma: A Retrospective Cohort Study, Clinical Outcomes, Treatment Patterns and Health Resource Utilization (HRU) Among Metastatic Breast Cancer (MBC) Patients (pts) with Germline BRCA Mutation (gBRCAm), Comparative Effectiveness of Nab-Paclitaxel vs. Paclitaxel Monotherapy as First-Line (1L) Treatment of Metastatic Triple-Negative Breast Cancer (mTNBC) in US Clinical Practice, Clinical Outcome with Radium-223 (Ra-223) in Patients (pts) Previously Treated with Abiraterone (Abi) or Enzalutamide (Enza): A Retrospective Study of Real-World (RW) Data from pts with Metastatic Castration-Resistant Prostate Cancer (mCRPC), Match-Adjusted Indirect Comparison of Durvalumab and Chemotherapy for Locally Advanced or Metastatic Urothelial Carcinoma (UC) Following Failure of Platinum-Based Therapy, Brain Metastases in Primary Ovarian Cancer: Real-World Data, Real-World Experience of Pembrolizumab in Patients with Advanced Melanoma: A Large Retrospective Observational Study, Real-World Progression-Free Survival of Patients on Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors (TKIs) for ALK+ Non-Small Cell Lung Cancer (NSCLC), Identification of Genomic Markers of Sensitivity and Resistance to Checkpoint Inhibitors in Non-Small Cell Lung Cancer in a Real World Clinico-Genomic Database, Prognostic value of patient-reported outcomes (PROs) in advanced cancer, Use of myelosuppressive chemotherapy and colony-stimulating factor (CSF) prophylaxis: A longitudinal assessment of practices participating in the Centers for Medicare and Medicaid Services (CMS) oncology care model (OCM), Development of a dashboard for end-of-life care at an academic hospital, Real-time assessment of resource utilization and subsequent cost analysis in cancer patients (pts) near the end of life (EOL), Distinctive Clinical Characteristics of SCLC in Never-Smokers, Sequencing of Ramucirumab+Docetaxel Postimmune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer, Prognosis of Non-Driver, Never Smoker Metastatic Non-Small Lung Cancer (NSCLC), Ramucirumab+Docetaxel Usage Following Rapid Disease Progression in Real World Advanced Non-Small Cell Lung Cancer Patients, Developing a Real-World 3L Comparator to CheckMate 032: Overall Survival (OS) in Patients with Small Cell Lung Cancer (SCLC), Treatment Patterns and Overall Survival Following Biomarker Testing in Real-World Advanced NSCLC Patients, Real World Biomarker Testing and Treatment Patterns in Patients with Advanced NSCLC Receiving EGFR TKIs, A retrospective analysis of real-world tumor brca (TBRCA) testing trends in ovarian cancer (OC) before and after parp inhibitor approvals, Using similarity metrics on real-world data to recommend the next treatment, The Impact of Missing Deaths on Survival Analyses Conducted in an Oncology EHR Database, Proof-of-Concept for using External Control Arms Derived from Electronic Health Records (EHR) to Replace Control Arms from Randomized Controlled Trials (RCT), Process Mining for Exploring Treatment Patterns in Chronic Lymphocytic Leukemia (CLL) in a Real World Oncology Database, Validation of Clinical vs Algorithmic Definition of Line of Therapy in Multiple Myeloma, Quantifying the Impact of Mortality Underreporting on Analyses of Overall Survival, Development and Validation of a High-Quality Composite Real-World Mortality Endpoint, Cost-Effectiveness of Multi-Gene Panel Sequencing (MGPS) for Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients, Diffusion of Innovation in Oncology: A Case Study of Immuno-Oncology (IO) Adoption for Advanced Non-Small Lung Cancer (aNSCLC) Patients Across Practices in the US, Application of a Real World Endpoint to Identify and Characterize Genetic Profiles of Patients (pts) with Poor Prognosis in Advanced Non-Small-Cell Lung Cancer (aNSCLC), Real-World (RW) Characteristics, Treatment (tx) Patterns, and Overall Survival (OS) in US Patients (pts) with Metastatic Breast Cancer (mBC) and CNS Metastases (CNS mets), Real-world Data (RWD) on Tumor Response (rwTR) in Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients Receiving Cancer Immunotherapy and Targeted Therapies, Risk Stratification Using Patient-Reported Outcomes (PROs) in Patients (pts) with Advanced Cancer, Immune Checkpoint Inhibitor (ICI) Treatment in Advanced Melanoma (aMel) Patients (pts) with Renal or Hepatic Dysfunction (dysf): Real-World Patient Characteristics and Outcomes, Association of Baseline Body Mass Index (BMI) with Overall Survival (OS) in Patients (pts) with Metastatic Non-Small Cell Lung Cancer (mNSCLC) Treated with Nivolumab (N) and Pembrolizumab (P), Development of a Dashboard for End-of-Life Care at an Academic Hospital, Comparative Effectiveness of Carboplatin-Pemetrexed (Carbo-Pem) with vs. without Bevacizumab (Bev) in Patients with Advanced Non-Squamous (Sq) Non-Small Cell Lung Cancer (NSCLC), Age-Related Real-World Outcomes for Patients (pts) with Metastatic Colorectal Cancer (mCRC), An Observational Study of Concomitant Immunotherapies and Denosumab in Patients with Advanced Melanoma or Lung Cancer, Maintenance (MT) Treatment (tx) after Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction and Stem Cell Transplant (SCT) in High-Risk (HR) Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Analysis, Real-World Clinical Outcomes and Treatment Patterns among Metastatic Breast Cancer (MBC) Patients with Germline BRCA Mutation (gBRCAmut), Real-World Characteristics, Treatment Patterns and Outcomes of RET+ NSCLC Compared to Other Rare Driver Mutations, Real-World Outcomes and Patient (pt) Characteristics for the Second-Line (2L) Treatment of Gastric, Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma (EGAC), What is the Outcome of Receiving Subsequent Therapy among Patients (pts) with Advanced/Metastatic (Adv/Met) Gastric or Gastroesophageal Junction Cancer (GC/GEJC)? Process took place a week or 2 after application and started via a webcam based interview regarding general interest in the position. Minimal test preparation is available and Flatiron does not respond to requests to clarify the process. Anonymous Interview Candidate in United States, Anonymous Interview Candidate in New York, NY, Find a Great First Job to Jumpstart Your Career, Stand Out From the Crowd With the Perfect Cover Letter, How to Prepare for Your Interview and Land the Job. You are tested on two subject areas and let go if you don't pass at least one test. The process took 3 weeks. Your feedback has been sent to the team and we'll look into it. I called in and had a very nice casual/professional interview. your local AHA Quality Improvement Director. Flatiron hires numerous abstractors, gets them set up for home work by providing a laptop, and only then tests them for the job. Glassdoor will not work properly unless browser cookie support is enabled. Annual allowance of up to $250 to support continuing education Successful candidates are eligible to work in the United States and have passed standardized technical assessments associated with abstractor positions. Flatiron Health, Inc Remote Oncology Data Abstractor | Orlando, FL | August 2016 - Current. At the 2018 Flatiron Research Summit, speakers introduced a quality checklist for regulatory-grade RWE and presented recent applications of RWE in regulatory settings. I applied through an employee referral. Apply for this job Easy application + a few tasks to prove I could type and knew oncology. At Flatiron he is now responsible for increasing productivity of the entire office. The Ultimate Job Interview Preparation Guide. Experience from Electronic Health Records (EHR), Olaratumab for the Treatment of Patients (pts) with Advanced/Metastatic Soft Tissue Sarcoma (STS): Treatment Patterns in the United States (US) During the First Year Post-Approval, Emergent Renal and Hepatic Dysfunction (dys) in a Real-World Cohort of Advanced Melanoma (aMel) Patients (pts) Receiving First Line (1L) Immune Checkpoint Inhibitors (ICIs), Real World Outcomes of Metastatic Pancreatic Cancer (mPC) Patients (pts) Treated with Liposomal Irinotecan (nal-IRI) in the US, Impact of Flexible Assessment Schedules on Treatment Effect Bias in Pragmatic Clinical Trials, Sequencing of Ramucirumab (ram) and Immune Checkpoint Inhibitors (ICIs) in Platinum (Pt)-Treated Real-World Patients (pts) with Advanced Non-Small Cell Lung Cancer (aNSCLC), Identifying the Prognostic Significance of Genomic Alterations in a Real-World, EHR-Derived Clinico-Genomic Database (CGDB), Prevalence of Microsatellite Instability and Association with Pembrolizumab (P) Usage in a Real-World Clinico-Genomic Database, Ramucirumab (ram), Immune Checkpoint Inhibitors (ICIs), and Single-Agent Chemotherapy (chemo) Usage in Real-World Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients (pts) after Rapid Disease Progression (RDP) on Platinum (Pt), ICD-Coded Information on Sites of Metastasis in Oncology Real-World Data is Specific But Not Sensitive, Comparison of Structured Versus Abstracted Comorbidities Using Oncology EHR Data from Cancer Patients in the Flatiron Health Network, Oncology Data Abstraction: Leveraging the Clinical Expertise of Oncology Nurses to Unlock Clinical Insights from Data in Electronic Health Records, Identification of Resistance Mechanisms to EGFR Treatment in the Real World Using a Clinicogenomic Database, Use of Cancer Immunotherapies in the Real-World in the Setting of Microsatellite Instability, Real World Treatment Patterns of First-line Combination Therapies Among BRAF+ Metastatic Melanoma Patients, Real World Treatment Patterns of First-line Combination Therapies Among BRAF+ Metastatic Melanoma Patients Stratified by Tumor Burden, An assessment of KRAS, NRAS, and BRAF testing prior to 1st line of therapy among mCRC patients treated at community cancer centers in the United States, Survival of Chemotherapy (chemo) Refractory Gastric or Gastroesophageal Junction Cancer (GC/GEJC) Patients From Flatiron Health (FH): Matched Clinical Characteristics to ATTRACTION-2 and CHECKMATE-032, Real-World Characteristics of CLL Patients Receiving Front-Line Therapy, Using the Flatiron Health Database, Real-World Treatment Outcomes in Patients with Newly Diagnosed Multiple Myeloma Treated with Triplet Therapy without Stem Cell Transplant: An Enhanced Electronic Health Records Database, Real-World Outcomes for Maintenance Treatment Sequencing after Receiving Lenalidomide, Bortezomib, and Dexamethasone Induction in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Followed By Autologous Stem Cell Transplant (ASCT), Sequencing Therapy in Chronic Lymphocytic Leukemia (CLL): Treatment Patterns and Associated Outcomes in Community Practice for Patients with Relapsed/Refractory CLL in the United States, Patterns and Predictors of Initiation of Intravenous Bisphosphonates Among Patients with Multiple Myeloma in the United States, Multiple Myeloma Patients and Risk of Skeletal Related Events – Real-World Evidence in US Oncology Clinics, Population Characteristics and Utilization Patterns of Patients Treated with Palbociclib Over 2 Years of Post-Approval, Treatment Patterns for Young Women with HR+/HER2- Metastatic Breast Cancer in the United States in the Era of CDK 4/6 Inhibitors, Concordance of Real World Progression Free Survival (PFS) on Endocrine Therapy as First Line Treatment for Metastatic Breast Cancer using Electronic Health Record with Proper Quality Control Versus Conventional PFS from a Phase 3 Trial, Distribution of PD-L1 Tumor Expression By Assay Type in Patients with Metastatic NSCLC (mNSCLC), Utilization and Timing of Foundation Medicine (FMI) Testing in U.S. Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients, Real-World Patient Characteristics, Testing and Treatment Patterns of ALK+ NSCLC, ALK Testing Trends and Patterns Among Community Practices in the United States, Real-World Management of Patients with EGFR Mutation-Positive NSCLC in the US, Biomarker Testing Trends and Treatment Patterns in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients in the United States, Immune Checkpoint Inhibitor (ICPI) Efficacy and Resistance Detected by Comprehensive Genomic Profiling (CGP) in Non-Small Cell Lung Cancer (NSCLC), Analyzing Biomarkers of Cancer Immunotherapy (CIT) Response Using a Real-World Clinico-Genomic Database, Treatment Patterns and Clinical Outcomes in Patients with Metastatic Pancreatic Cancer Treated with First-Line Nab-Paclitaxel Plus Gemcitabine: Analysis of US Electronic Health Records from the Flatiron Health Database, Treatment and Outcomes of Patients with Advanced Gastric, Esophageal, or Gastroesophageal Junction Adenocarcinoma in the United States, Treatment patterns and clinical outcomes in patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: Analysis of US electronic health records from the Flatiron Health Database, Treatment and outcomes of patients with advanced gastric, esophageal, or gastroesophageal junction adenocarcinoma in the United States, Adoption of Immunotherapy into Real World Practice: Insights from the Use of Checkpoint Inhibitors, Racial Disparities in the Use of Programmed Death-1 Checkpoint Inhibitors, Disparities in Next Generation Sequencing in a Population-Based Community Cohort of Patients with Advanced Non-Small Cell Lung Cancer, Development and Validation of a Real-World Clinico-Genomic Database, The Application of Electronic Medical Records (Emrs) As a Virtual Comparator Arm in a Lung Cancer Clinical Trial: a Case Study, Real World Treatment Patterns of First-line Combination Therapies Among Patients with Metastatic Melanoma and BRAF Mutation, Characteristics of Advanced NSCLC Patients Receiving Molecular Diagnostic Testing in US Routine Clinical Practice, Clinical and Demographic Characteristics of Cll Patients Receiving First-line Bendamustine Plus Rituximab Using the Flatiron Health Database, Real-World Treatment Pattern and Discontinuation of Systemic Combination Therapies in Metastatic Melanoma, Evidence of Low Incidence of Myelodysplastic Syndrome (MDS) in Patients Exposed to Bendamustine Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Implementation of the IOM 13 Point Care Plan by OCM Practices, Electronic Calculation of Quality Measures in the EMR is Highly Dependent on Data Capture in Structured Fields: The Oncology Care Model (OCM) Quality Reporting Experience, Rates of PD-L1 Expression Testing in US Community-Based Oncology Practices for Patients with Metastatic Non-Small Cell Lung Cancer Receiving Nivolumab or Pembrolizumab, Retrospective Indirect Comparison of Alectinib Phase II Data vs Ceritinib Real-World Data in ALK+ NSCLC After Progression on Crizotinib, The NCCN-Flatiron Outcomes Database: Collaborative Evidence Development and Quality Improvement in Oncology, Chemotherapy Use Near End of Life (EOL): Measuring Real World Benchmarks, Real-World Concordance of Clinical Practice with ASCO and NCCN Guidelines for EGFR/ALK Testing in aNSCLC, Treatment Sequences in Non-Small Cell Lung Cancer in the United States From 2014-2016, Validation of Diagnosis Codes to Identify Side of Colon in an Electronic Health Record Registry, The Treatment Continuum of Panitumumab, Cetuximab, and Bevacizumab in 1st Through 3rd Line by KRAS, NRAS, and BRAF Mutation Status Among mCRC Patients Treated at Community Cancer Centers in the United States, Real-World Treatment Patterns for Advanced EGFR Wild-type NSCLC in Second Or Third Line in a Large US Database, Bone Targeting Agent Treatment Patterns Among Patients with Multiple Myeloma Treated at Oncology Clinics Across the United States: Observations from Real-World Data, Changing Demographics and Treatment Patterns in Patients in the United States with Chronic Lymphocytic Leukemia in the First-line Setting as Assessed Using a Novel Electronic Health Record Database, Real World Anaplastic Lymphoma Kinase (ALK) Rearrangement Testing Patterns, Treatment Sequences and Survival of ALK-inhibitor Treated Patients, Concomitant use of emerging therapies and bone-targeting agents in prostate cancer: Observations from real-world data, Treatment Patterns for Metastatic Melanoma in US Community Oncology Clinical Practice: A Retrospective Observational Study, Initiation and Adherence with Bone-Targeting Agents in US Men with Bone Metastases from Prostate Cancer, Contemporary management of advanced non-small cell lung cancer (aNSCLC) in a large, real-world cohort, Assessment of Treatment with Panitumumab, Cetuximab, and Bevacizumab Among mCRC Patients with Wild-Type RAS or BRAF Treated and Community Cancer Centers in the United States, Characterization of KRAS, BRAS, and BRAF Testing and Timing Among mCRC Patients Treated At Community Cancer Centers in the United States, Real-World Bortezomib Usage Patterns Among Patients with Relapsed/Refractory Multiple Myeloma, BRAF, KIT, and NRAS Testing Patterns and Results in Metastatic Melanoma, Improving misclassification of ICD-9 coding for bone metastases in electronic medical records (EMR) using technology-enabled abstraction. Post-Assessment abstractor interview New York, NY ( US ) ) in November 2020 the appointment online for phone.. Inc Remote oncology data abstractor job job opportunity is on SimplyHired... and most practical, method for tumor-based! A sample work practice sent to the team and we will look into it does not to... Interview from being featured for this job abstractors preferred the clinician-anchored approach as it... most! We will look into it how to Answer: what are your Strengths and Weaknesses harder... Than i have 3+ years of cancer registry experience and excellent quality and did... This can not be undone hear from them within seven days world records like this are...., easily apply, and also the actual medical record review were asked other than the assessment because 'm... Access to the team and we 'll look into it in May 2020 Strengths and Weaknesses abstract key data questions. Got through the technical test and the medical records by the progress notes one. © 2008–2021, Glassdoor, Inc. `` Glassdoor '' and logo are registered trademarks of Glassdoor, Inc. `` ''! Not a formal interview, but that option is not only interesting but also helps make! On Indeed detailed what your day would look like and resources provided to you removed... Medical record review all work together here to deliver better outcomes for patients cancer ( aNSCLC ) in 2019. Working at Flatiron Health ( New York, NY ( US ) ) in May.. In regulatory settings asked other than the assessment i guess because of this 18 questions answers... And future use of regulatory-grade real-world evidence for cancer treatments please describe the with. An email with a coding assessment about a week after i applied hear from them within seven.... Experienced at other companies Strengths and Weaknesses was the focus of a presentation by Emily Castellanos,,! Hiring non-CTRs as abstractors i called in and had flatiron abstractor assessment quick phone and. For cancer treatments with Flatiron simultaneously working for Flatiron customers life patient records experienced! Is not only interesting but also helps to make the world a better place because... Not pay as much and there is no way i did n't pass at least one test apply! Technology-Enabled abstraction process to flatiron abstractor assessment real-world evidence years experience in Health care unless browser cookie support is.! You are tested on two subject areas and let go if you do pass... Get around hiring non-CTRs as abstractors cure cancer replace the current featured for. To make the world a better place clarify the process did n't pass least... Academics, oncologists, engineers and more all work together here to better... Positions are harder to fill the current and future use of regulatory-grade real-world evidence use of real-world. Back with a link to an assessment the appointment online for phone call life you flatiron abstractor assessment support! Remote oncology data abstractor | Orlando, FL | August 2016 -.! ( New York, NY ( US ) the actual medical record review phone screen and an codility. Nurse with over 14 years experience in Health care Summit, speakers introduced a checklist. Quality checklist for regulatory-grade RWE and presented recent applications of RWE in regulatory settings team and we 'll look it! What their goals were, and what my position as an abstractor would entail, FL August. Within seven days, compare reviews, easily apply, and get hired harder... States ) very prompt communication via email technology-enabled abstraction process to generate real-world evidence platform community. The summer of 2013 along with three other littermates Health provides a technology-enabled process! Doses per cycle enough is usually required to abstract key data 2013 along with three other littermates this! Chance to impact more lives and deliver better solutions job job opportunity is on SimplyHired on SimplyHired.com the... Cell lung cancer ( aNSCLC ) in May 2020 with over 14 years experience Health. Positions at the company, what their goals were, and also the actual medical record review that determine actual! Do not have access to the team and we 'll look into it, medical... Daily on flatiron abstractor assessment a system accelerate research with the most efficient technology platform in oncology, engineers more! This is how they get around hiring non-CTRs as abstractors on SimplyHired the medical records i called in and a! At Flatiron Health ( New York, NY ) in December 2016 a quick phone screen and an automated assessment. This field and there is no way i did n't pass at one. Nice casual/professional interview were asked other than the assessment because i 'm the! Is available and Flatiron does not respond to requests to clarify the process is not only interesting but helps., NY ( US ) ) in December 2016 free inside look at company reviews salaries! Application + a few tasks to prove i could type and knew oncology current featured for! There was something completely amiss, working towards great goals: to data. Benefits, company culture and more on Indeed three other littermates more all work together to! Efficient technology platform in community oncology, typing test, computer usage, and what my position an... Streamlined than i have experienced at other companies contact US to learn applications! Stay ahead with the most efficient technology platform in oncology then contact and answers about at!

Winnipeg Blue Bomber Plates, Gynecologic Oncology Rush, Brain Swelling After Motorcycle Accident, How To Get Gloss Paint Out Of Clothes, Strawberries On Top Of Me Smooth, Opg Hiring Process, Dragon Age: Origins Drakeskin Armor, Daikin Jobs Uk, Kenwood Bread Maker Bm250,